Grifols (GIKLY) Other Non-Current Assets (2009 - 2025)
Grifols (GIKLY) posted Other Non-Current Assets of $27.9 million for Q4 2025, down 31.2% quarter-over-quarter from $40.6 million in Q4 2024, and down 31.2% year-on-year from $40.6 million in Q4 2024.
Grifols (GIKLY) Other Non-Current Assets (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Other Non-Current Assets for 15 consecutive years, with $27.9 million the latest figure, recorded in Q4 2025.
- Other Non-Current Assets for Q4 2025 came in at $27.9 million, down 31.2% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.9 million (down 31.2% YoY), and the FY2025 annual result was $27.9 million, down 31.2% from the prior year.
- Other Non-Current Assets was $27.9 million for Q4 2025 at Grifols, down from $40.6 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $298.9 million in Q4 2021 and troughed at $27.9 million in Q4 2025.
- Average Other Non-Current Assets over 5 years is $128.0 million, with a median of $126.7 million recorded in 2022.
- Year-over-year, Other Non-Current Assets surged 132.07% in 2021 and plunged 72.17% in 2024.
- Over 5 years, Other Non-Current Assets stood at $298.9 million in 2021, then tumbled by 57.61% to $126.7 million in 2022, then grew by 15.17% to $145.9 million in 2023, then slumped by 72.17% to $40.6 million in 2024, then plunged by 31.2% to $27.9 million in 2025.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $27.9 million in Q4 2025, $40.6 million in Q4 2024, and $145.9 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.23 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 14.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 10.54 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 200.00 Mn |
| 10 | Grifols | - | - | - | 27.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27.94 Mn |
| Dec 31, 2024 | 40.61 Mn |
| Dec 31, 2023 | 145.93 Mn |
| Dec 31, 2022 | 126.71 Mn |
| Dec 31, 2021 | 298.91 Mn |
| Dec 31, 2020 | 128.80 Mn |
| Sep 30, 2020 | 147.64 Mn |
| Mar 31, 2020 | 145.22 Mn |
| Dec 31, 2019 | -15.35 Mn |
| Sep 30, 2019 | 133.28 Mn |
| Mar 31, 2019 | 137.44 Mn |
| Dec 31, 2018 | 2.18 Mn |
| Sep 30, 2018 | 78.26 Mn |
| Jun 30, 2018 | 10.24 Mn |
| Mar 31, 2018 | 75.04 Mn |
| Dec 31, 2017 | 77.90 Mn |
| Jun 30, 2017 | 5.72 Mn |
| Dec 31, 2016 | 1.16 Mn |
| Sep 30, 2016 | -723,287.54 |
| Jun 30, 2016 | 5.24 Mn |